LEO Pharma and Elektrofi Expand Partnership to Co-Develop New Antibodies with the Aim of Achieving Improvements in Drug Delivery within Dermatology

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a
Boston- based biotechnology company focused on drug formulation and
delivery innovations, today announced an expansion of the two companies’
partnership agreement (signed in 2017) to further include antibodies
from LEO Pharma’s pipeline with the aim of achieving improvements in
drug delivery within dermatology.

As part of the agreement LEO Pharma and Elektrofi will initially
co-develop two specific anti-bodies. The agreement includes an option to
a pre-negotiated license for the potentially improved antibodies in the
pre-clinical and clinical stage. LEO Pharma and Elektrofi will work
closely together in an alliance to enable a lower injection volume for
subcutaneous administration and, in turn, enable novel formulations and
better convenience for patients.

“At LEO Pharma we are working constantly to find innovative ways to help
people with skin diseases and improve their quality of life. Together
with Elektrofi, we hope to find new, more convenient solutions for drug
delivery, which potentially will be of benefit to patients,” said Kim
Kjøller, executive Vice President, Research & Development, LEO Pharma.

“We are excited to further our partnership with LEO Pharma, who we
consider to be a leader in patient centric innovation. This flagship
deal for our growing company is an exciting consummation of a close
partnership over the last 2 years. The biopharma industry’s continued
shift to subcutaneous administration is a reflection of patients’ demand
for convenience. Elektrofi is thrilled to utilize its technology with
LEO Pharma to improve patients’ lives,” said Jason Norris, Cofounder,
Elektrofi.

About Elektrofi’s technology: Elektrofi leverages its microparticle
suspension formulation technology (Elektroject^TM) to enable
syringe-compatible injections of high-dose antibody therapeutics. Most
antibody solutions are unusable in syringes at high concentrations due
to concentration associated syringe forces that exceed human ability,
leaving drug developers to either increase dose frequency or administer
prolonged, large-volume infusions. Elektroject^TM suspensions
enable clinicians and patients to administer high doses of antibody
therapies in a relatively small volume within seconds in addition to
providing improved product stability at full quality.

See the full press release in the attached document

Contacts

For further information, please contact:
Elektrofi,
Inc
Jason Norris, Cofounder
Email: [email protected]

LEO Pharma A/S
Trine Juul Wengel
Tel.: +45 20732037
Email:
[email protected]